Biopharmaceutical company PTC Therapeutics Canada ULC announced Wednesday that Health Canada has approved Sephience (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU).
The approval includes broad labeling for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month old and older with sepiapterin-responsive PKU.
The Health Canada approval is based on the evidence of significant efficacy and safety from the Phase 3 APHENITY trial as well as durability of treatment effect in the APHENITY long-term extension study.
Sephience is now commercially available in Canada. Sephience was recently approved by the U.S. Food and Drug Administration and granted marketing authorization by the European Commission.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.